NEFFY (epinephrine) by ARS Pharmaceuticals is adrenergic alpha-agonists [moa]. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 4d ago
NEFFY is a nasal spray formulation of epinephrine, an alpha-adrenergic agonist approved by the FDA in August 2024. It is indicated for emergency treatment of anaphylaxis and leverages a novel intranasal delivery mechanism to provide rapid systemic absorption. The drug represents a new route of administration for a well-established active pharmaceutical ingredient.
Early-stage growth product with zero current competitive pressure; brand team will focus on market education, hospital formulary placement, and patient/provider awareness campaigns.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Worked on NEFFY at ARS Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moNEFFY represents a rare opportunity to join a launch-stage, first-in-class product with zero competitive threats and a 12+ year exclusivity window. Professionals working on this brand will drive early market definition, physician education, and rapid scaling in a high-stakes emergency medicine segment.